Meningococcemia screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
:*to detect outbreaks of meningococcal [[disease]] so that appropriate control measures can be promptly instituted, and | :*to detect outbreaks of meningococcal [[disease]] so that appropriate control measures can be promptly instituted, and | ||
:*to assess changes in the epidemiology of meningococcal [[disease]] over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies. | :*to assess changes in the epidemiology of meningococcal [[disease]] over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies. | ||
*Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate [[vaccine]]. Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations. | *Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate [[vaccine]]. Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html}}</ref> | ||
<ref name=CDC>{{cite web | title = The Centers for Disease Control and Prevention(CDC)| url =http://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:14, 26 November 2014
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia screening On the Web |
|
American Roentgen Ray Society Images of Meningococcemia screening |
|
Risk calculators and risk factors for Meningococcemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Routine screening is not recommended for meningococcemia.
Screening
- Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended.
- Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in N. meningitidis susceptibility.
- State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to ciprofloxacin or other agents used for treatment or prophylaxis is detected.
- Passive and active surveillance systems are used to monitor meningococcal disease, which is a reportable disease in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS).
- The goals of meningococcal surveillance are
- to detect outbreaks of meningococcal disease so that appropriate control measures can be promptly instituted, and
- to assess changes in the epidemiology of meningococcal disease over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies.
- Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate vaccine. Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.[1]